Here you can see at a glance why this vaccine should be withdrawn worldwide and ask yourself why do health officials promote such dangerous, ineffective, unaffordable and unnecessary vaccine programmes. CHS has previously reported on this vaccine:

SaneVax is an international non-profit organization working with representatives in over 25 countries. SaneVax believes vaccines should be scientifically proven safe, affordable, necessary and effective. The SaneVax Team say they cannot support HPV vaccination programs for the following reasons:

#1 HPV VACCINES ARE NOT SAFE

HPV vaccines account for nearly 25% of the reports on the USA’s Vaccine Adverse Event Reporting System (VAERS) database. VAERS was established in 1990. HPV vaccines were introduced 16 years later in mid-2006. And there are over 80 other vaccines approved for use in the United States. Since the introduction of HPV vaccines [including Gardasil and Cervarix]:

reports of Acute Disseminated Encephalomyelitis [ADEM] have increased over 1,000%;

infertility reports increased 790%;

reports of blindness increased 188%;

spontaneous abortions by 270%.

when 24,000 girls were injected with HPV vaccines during ‘demonstration projects’ an estimated 5% (1200) were left with chronic health problems and/or autoimmune disorders;

Japan withdrew the government recommendation for the administration of HPV vaccines after only 6 weeks when reports of adverse events after Gardasil were 26 times higher than the annual flu shot;

reports after Cervarix were 52 times higher than the annual flu shot;

24.9% of the adverse events reported were considered serious.

Denmark reports that 24% of the adverse events reported after HPV vaccinations were considered serious.

adverse events reports in Italy are ten times higher than most other vaccines – at a rate of 219/100,000. The cervical cancer rate in Italy is 7.7/100,000.

#2 HPV VACCINES ARE NOT AFFORDABLE

HPV vaccination programs do not eliminate the need for pap screening, they simply add the price of 3 injections to already overburdened healthcare systems around the globe.

There is an already proven safe and effective method of controlling cervical cancer in most developed countries – pap screening and good gynecological follow-up. Countries without this practice in place would be money ahead to spend their healthcare budget developing the infrastructure to provide this type of care.

Cervical cancer causes 2.3 deaths/100,000 women in the United States. The cost of 3 doses of HPV vaccine for 100,000 women is an estimated $30,000,000 ($100/dose) to try and eliminate less than 3 deaths which could have been avoided with pap screening and good gynecological follow-up. How many medical professionals could be trained and/or medical facilities built with that same 30 million dollars?

#3 HPV VACCINES ARE NOT NECESSARY

The human papillomavirus has never been proven to cause cancer by itself. Other risk factors must also be present in order to prompt the development of cancer.

According to the World Health Organization, only 0.15% of all people exposed to any high-risk strain of HPV will ever develop cervical cancer. The vast majority of HPV ‘infections’ are benign and cause no medical problem whatsoever.

HPV type prevalence varies greatly from one region to the next. Are the HPV types targeted by current vaccines the same ones prevalent in your country?

There is no excuse for exposing the female population of the world to the risks involved with HPV vaccination when there is an already proven safe, affordable, necessary and effective means of controlling cervical cancer.

#4 HPV VACCINES ARE NOT EFFECTIVE

According to the World Health Organization, only 1% of CIN1 progresses to the next stage, only 1.5% of CIN2 progresses. Only 12% of CIN3 lesions, which are actually considered a pre-cursors to cancer. Nevertheless, the FDA allowed the manufacturers of HPV vaccines to use these often self-reversing abnormal lesions as endpoints to judge the efficacy of their products.

The other endpoint used to predict efficacy was antibody titers. No one has determined what level of antibodies is necessary to prevent HPV infections. It is simply assumed that the higher the antibody titer level, the better the potential protection.

HPV vaccines have not been clinically proven to prevent a single case of cancer.

There is no guarantee that eliminating one risk factor for the development of cervical cancer will have any impact on the disease incidence or mortality rate.

It will take more than 20 years to determine whether or not HPV vaccines perform as advertised.

There is no guarantee that any suppressed oncogenic HPV type will not mutate over the next 20 years and become more dangerous.

The video below shows with references to peer reviewed citations in journal papers that the US Centers for Disease Control medical scientists engage in using peer reviewed journal publications, in this case Health Economics, to promote Hep B vaccine on false and made up figures. Hepatitis B vaccine is given to every US baby immediately following birth when the disease risk is predominantly to intravenous drug abusers and practitioners of unsafe sex and not babies. Hepatitis B vaccine has a reputation as a particularly toxic vaccine: UK Government Caught Lying On Baby Hep B Vax Safety.

This 7 minute video contains citations to peer reviewed journal publications showing the CDC falsifying disease data to promote the Hep B vaccine by claiming 250,000 hepatitis cancer deaths in India and published this in a journal paper. The paper claims a death rate at 5000% of the true figure such that the vaccine is being promoted on a completely false basis which cannot be justified on the basis of the true figures.

There are a number of problems with this report. When precautionary measures are needed, the evidence the public need is that the vaccine did not kill, not that there is no evidence it did. There appears to be no evidence the vaccine did not kill the 13 victims. There is evidence the deaths followed very shortly after the vaccine. Vaccines are fast tracked and not properly tested for safety. They are not subjected to the “gold standard” of testing – the randomised placebo controlled trial.

And as a public health measure they do not work – yet health authorities continue to push flu vaccines on the population not because they do work but because these are mass experiments on living human populations with products which are not proven safe. And then the adverse reactions are heavily under-reported and the data misreported to pretend dangerous vaccines are safe, as CHS has reported previously:

Italy has suspended the use of two batches of the Fluad flu vaccine made by Novartis after 13 people died shortly after the treatment was administered.

………..

The episode occurs shortly before Novartis is due to transfer its vaccines business to GlaxoSmithKline as part of an asset swap deal in which Glaxo will transfer most of its cancer portfolio to Novartis. A Glaxo spokeswoman declined to comment.

This is the not the first time that Novartis has run into difficulties with vaccines produced in Italy. Two years ago, the drug maker suffered what it called a “data-handling discrepancy,” which caused some vaccines to be temporarily and voluntarily held for several months. Novartis inspected its manufacturing practices and submitted reports to the EMA and AIFA before shipments resumed.”

How to declare a vaccine programme a success? Redefine the disease and then claim it is being eradicated with a vaccine whilst still causing paralysis under a different name “Non Polio Acute Flaccid Paralysis“.

India has provided the evidence to indicate that Non Polio Acute Flaccid Paralysis is a disease associated with the polio vaccine. The vaccine contains live polio virus, so when administered artificially is a means of causing a polio infection.

The LiveMint article reports:

Two doctors from Delhi’s St Stephens Hospital, Neetu Vashisht and Jacob Puliyel, who compiled data from the national polio surveillance project, found a link between the increase in dosage of polio vaccination and the increasing cases of NPAFP.

“Most experts will tell you the cases of NPAFP have increased because of better surveillance. This is bunkum,” said Puliyel. “As per global benchmarks, as polio incidence comes down, the rate of NPAFP should also reduce. Instead, AFP cases have been increasing steadily.”

“In 2010, the government reduced the number of pulse polio doses from 10 to 6. What we found was that between 2010-2013, the number of APF cases also came down. Our paper argues that other kinds of polio are being caused by the excessive administration of polio dosages,” Puliyel said. “Another proof is that states like Kerala and Goa, where dosages were less, AFP cases was also less. Majority of NPAFP cases are reported from Bihar and UP, where several immunization rounds are held to reach universal coverage. These are figures the government does not want to admit.”